Search
deflazacort (Emflaza)
Indications:
- treatment of Duchenne muscular dystrophy in children >= 5 years of age [1]
Dosage:
- 0.9 mg/kg/day PO once daily.
- tablet, oral suspension
Adverse effects:
- similar to other glucocorticoids
Mechanism of action:
- glucorticoid that reduces inflammation
- oxazoline derivative of prednisolone
Interactions
drug adverse effects of glucocorticoids
monitor with drug (more general terms)
General
glucocorticoid
Database Correlations
PUBCHEM cid=189821
References
- FDA News Release. February 9, 2017
FDA approves drug to treat Duchenne muscular dystrophy.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm540945.htm
- Windle ML.
FDA New Drug and Biologic Approvals -- 2017 Year-in-Review
Medscape - Jan 11, 2018.
https://reference.medscape.com/viewarticle/890871
- U.S. Food and Drug Administration.
Novel Drug Approvals for 2017.
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
- Griggs RC, Miller JP, Greenberg CR et al
Efficacy and safety of deflazacort vs prednisone and placebo
for Duchenne muscular dystrophy.
Neurology. 2016 Nov 15;87(20):2123-2131. Epub 2016 Aug 26.
PMID: 27566742 Free PMC Article